Pine Valley Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

Pine Valley Investments’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.6K	Buy	+16,506	New	+$55K	﹤0.01%	596

Other funds holding RXRX

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Carroll Investors Mt Pleasant, South Carolina $234M AUM 59.79% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Allen Operations New York $722M AUM 20.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Pine Valley Investments's RXRX Position: Q2 2026 in Review

Pine Valley Investments opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 16,506 shares worth $60.6K. The stake represents ﹤0.01% of the portfolio and ranks #596 among its holdings.

124 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Pine Valley Investments held 16,506 shares of Recursion Pharmaceuticals worth $60.6K as of Q2 2026.
Recursion Pharmaceuticals was a new Pine Valley Investments position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Pine Valley Investments's portfolio in Q2 2026, its #596 holding.
124 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Pine Valley Investments's 13F filing for Q2 2026, filed 24 Jul 2026.